Roche Palo Alto LLC

Hoffmann-la Roche Inc.

Other

Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.

Jn Therapeutics

F. Hoffmann-la Roche Ag

Minmin Yang

Li Chen

Michael Patrick Dillon

Lichun Feng

Ronald Charles Hawley

Uwe Grether

Hans G Richter

Rainer Eugen Martin

Konrad H Bleicher

Gregory Martin Benson

Jean-Marc Plancher

Sven Taylor

Bernd Kuhn

Jin Li

Yingjie Lai

Wenshan Hao

Henrietta Dehmlow

Denis John Kertesz

Shung C Wu

Matthew Wright

Narendra Panday

Alexander Chucholowski

Eric Joseph Niesor

Christine E Brotherton-Pleiss

Franz Schuler

Shung Wu

Denis John Kestesz

Xavier Marie Warot

Linchin Feng

Liu Liu

Sean Chen

Provided herein are substituted imidazo[1,2-a]pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a Janus kinase-mediated disease.

Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof

Provided herein are substituted imidazo[1,2-a]pyridin-2-ylamine compounds, for example, of formula (A), and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a Janus kinase-mediated disease. 

Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof

A method of antagonizing P2Xand/or P2Xreceptors or treating a disease misregulation of P2Xand/or P2Xreceptors treating a patient with a compound of formula I wherein R, R, R, R, Rand Rare as defined herein, or a pharmaceutically acceptable salt thereof. wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

[object Object]

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted pyrazolyl, and R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

A method for treating diseases mediated by a P2Xand/or a P2Xreceptor with compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris an optionally substituted thiazole, oxazole, isothiazole or isoxazole and X, R, R, R, R, R, Rand Rare as defined herein.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris a group of formula A or formula B, and X, R, R, R, R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2Xand/or a P2Xreceptor antagonist and methods of making the subject compounds.

Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula V: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted phenyl, optionally substituted pyridin-2-yl or optionally substituted thienyl, and R, R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, R, RRand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted thiadiazolyl, and R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2Xand/or a P2Xreceptor antagonists and methods of making the compounds.

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, Ris optionally substituted tetrazolyl, Ris optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R, R, Rand Rare as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2Xand/or a P2Xreceptor antagonist and methods of making the compounds.

Growing community of inventors

Shanghai, China

Minmin Yang